Takeda Pharmaceutical Company Limited

Takeda Chemical Industries, Inc.

Takeda Pharmaceuticals U.s.a., Inc.

Yasushi Shintani

Takuya Watanabe

Yasuko Terao

Kazunori Nishi

Chieko Kitada

Tetsuya Ohtaki

Yukiko Hikichi

Shuji Hinuma

Ryo Fujii

Masaki Hosoya

Shoji Fukusumi

Tomohiro Kawamoto

Yasushi Masuda

Kimiko Kanehashi

Yoshihiro Takatsu

Kuniko Kikuchi

Masaaki Mori

Osamu Uchikawa

Yukio Shimomura

David L Baron

Tsukasa Sugo

Keisuke Hirai

Mioko Harada

Hideki Matsui

Syuji Hinuma

Shoichi Okubo

Takeo Moriya

Nobuyuki Miyajima

Tomomichi Watanabe

Takashi Horiguchi

Syuji Sato

David Baron

Pharmaceutical compositions and methods for treating and/or preventing age-related macular degeneration with melatonin analogues are provided.

Pharmaceutical compositions and methods for treating age-related macular degeneration with melatonin analogues

A compound that promotes the ubiquitination of a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence shown by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 or a partial peptide thereof or a salt thereof, or a salt thereof, a compound that promotes the degradation, by proteasome, of the protein or a partial peptide thereof or a salt thereof, or a salt thereof, and the like can be used as, for example, prophylactic/therapeutic agents for neurodegenerative disease. Also, a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence shown by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 or a partial peptide thereof or a salt thereof and the like are useful for screening for a compound having prophylactic/therapeutic action on neurodegenerative disease and the like or a salt thereof.

Screening method for an agent for treatment of neurodegenerative disease

The polypeptides in the present invention possess the effects of promoting and inhibiting the secretion of prolactin, and are thus useful as drugs for the prevention and treatment of various diseases, in terms of prolactin secretion stimulants, which are associated with the secretion of prolactin, such as hypoovarianism, spermatic underdevelopment, menopausal symptoms, hypothyroidism, etc. The polypeptides are useful as drugs for the prevention and treatment of various diseases, in terms of prolactin secretion inhibitors, which are associated with the secretion of prolactin, such as pituitary tumor, diencephalon tumor, menstrual disorder, autoimmune diseases, prolactinoma, sterility, impotence, amenorrhea, lactorrhea, acromegaly, Chiari-Frommel syndrome, Argonz-del Castilo syndrome, Forbes-Albright syndrome, lymphoma, Sheehan's syndrome, spermatogenesis disorder, etc.

Use of a G protein-coupled receptor and its cognizant ligand in the identification of compounds that affect prolactin secretion

The present invention relates to rat cerebellum-derived and human brain-derived G protein coupled receptor proteins or salts thereof, their partial peptides, amides, esters or salts thereof, ligands to the same, a method/kit for screening compounds that alter the binding property between the ligands and the G protein coupled receptor proteins, compounds obtained by the screening or salts thereof, and antibodies to the G protein coupled receptor proteins.

Screening assay using G-protein coupled receptor protein OT7T175

The present invention intends to provide a novel peptide and use thereof. More particularly, the present invention provides a novel peptide and a DNA encoding the same, a drug comprising the peptide or DNA, a screening method/screening kit for a compound or its salt that promotes or inhibits the activity of the peptide, a compound or its salt obtained by the screening, a drug comprising the compound or its salt, etc. The peptide of the invention and the DNA encoding the same are usable, e.g., for the diagnosis, treatment, prevention, etc. of digestive diseases, etc. Moreover, the peptide of the invention is useful as a reagent for screening a compound or its salt that promotes or inhibits the activity of the protein of the invention.

Isolated physiologically active peptide and use thereof

The present invention relates to a polynucleotide encoding a human brain-derived G protein coupled receptor protein. The human brain-derived G protein coupled receptor protein is useful: (1) for determination of a ligand to the receptor protein, (2) as an agent for the prevention and/or treatment of diseases associated with dysfunction of the receptor protein, (3) as a genetic diagnostic agent, (4) for quantification of a ligand to the receptor protein, (5) for screening of a compound that alters the binding property between the receptor protein and a ligand, (6) as an agent for the prevention and/or treatment of various diseases, comprising a compound that alters the binding property between the receptor protein and a ligand, (7) for quantification of the receptor protein, (8) for neutralization by antibodies to the receptor protein and (9) for preparation of a non-human animal bearing the DNA encoding the receptor protein.

Polynucleotide encoding the hOT7T175 G protein coupled receptor

The present invention relates to a screening method for a compound or a salt thereof that alters the binding property of MCH or a salt thereof to SLT or a salt thereof, or a partial peptide thereof, an amide or an ester thereof, or a salt thereof, characterized by using MCH, a derivative or a salt thereof and SLT or a salt thereof, or a partial peptide thereof, an amide or an ester thereof, or a salt thereof. The screening method of the present invention is useful for screening an SLT agonist, which can be used as an agent for promoting appetite (eating), and an SLT antagonist, which can be used as a prophylactic and/or therapeutic agent for obesity.

Method for screening MCH receptor antagonist/agonist

The present invention aims at providing a useful and novel G protein-coupled receptor protein and DNA thereof. The G protein-coupled receptor protein of the present invention and the like, and the polynucleotides encoding the receptor protein and the like, are useful for; 1) determination of ligands (agonists); 2) preparation of antibodies and antisera; 3) construction of recombinant receptor protein expression systems; 4) development of the receptor binding assay systems using the expression systems and screening of pharmaceutical candidate compounds; 5) effecting drug design based on comparison with structurally similar ligand receptors; 6) reagents for preparation of probes and PCR primers for gene diagnosis; 7) production of transgenic animals; and 8) pharmaceutical drugs for the gene prophylaxis and gene therapy.

G protein-coupled receptor protein and DNA thereof

G protein-coupled receptor protein, its DNA and ligand thereof

The screening method for a compound or a salt thereof that alters the binding property between Neuromedin U or a salt thereof and TGR-1 or a salt thereof, characterized by using Neuromedin U, a derivative thereof or a salt thereof and TGR-1 or a salt thereof, can be useful for screening a therapeutic and/or prophylactic agent for hypertension and stress-related diseases, etc. A TGR-1 antagonist can be useful as a therapeutic and/or prophylactic agent for hypertension and stress-related diseases, etc.

Screening method

Physiologically active peptide and use thereof

G Protein-coupled receptor proteins originating in the vicinity of rat brain stem and human brain or salts thereof, or peptide fragments thereof or amides, esters or salts of the same; ligands thereto; a method/kit for screening compounds capable of altering the binding properties of the ligands to the G protein-coupled receptor proteins; the compounds or salts thereof obtained by the above screening; antibodies against the G protein-coupled receptor proteins, etc.

Peptides that activate the G-protein coupled receptor protein, 0T7T175

This invention relates to glutamine:fructose-6-phosphate amidotransferase, or its partial peptide or a salt thereof; a DNA coding for the protein; a recombinant vector; a transformant; a method for producing the protein; a pharmaceutical composition comprising the protein, its partial peptide or a salt thereof; and an antibody against the protein or its partial peptide. The protein, its partial peptide or a salt thereof, and the DNA are useful for a prophylactic or therapeutic agent for hypoglycemia. The antibody can be used in the assay of the protein, its partial peptide or a salt thereof. The protein, its partial peptide or a salt thereof is useful as a reagent for the screening for candidate medical compounds.

Glutamine: fructose-6-phosphate amidotransferase, its production and use

This invention relates to a Fas ligand-like protein having an apotosis-inducing actibvity, etc. or its salt, a partial peptide of the protein or its salt; a DNA coding for the protein; a recombinant vector; a transformant; a method for producing the protein, a pharmaceutical composition comprising the protein, the partial peptide or its salt; and an antibody to the protein or the partial peptide. The protein, the partial peptide or its salt, and the DNA are useful as a prophylactic or therapeutic agent for cancer, viral infection, infection, invasive staphylococcia, hepatitis, nephritis, bone disease, atherosclerosis or pain. The antibody can be used in assay of the protein, the partial peptide or its salt. The protein, the partial peptide or its salt is useful as a reagent for the screening for candidate medical compounds.

Fas ligand-like protein, its production and use

This invention is directed toward novel human and murine Fas ligand-like proteins having an apoptosis-inducing activity. Cloned cDNAs encoding human, mouse, and rat Fas ligand-like proteins were obtained from human liver, mouse embryo, and rat liver cDNA libraries. The cDNAs were expressed in a recombinant yeast (e.g., Pichia) expression system. The expressed proteins should prove useful in a number of biochemical and immunological applications.

Growing community of inventors

Toyonaka, Japan

Yasushi Shintani